FDA grants emergency use authorisation to Quidel for first antigen test for Covid-19
The emergency use authorisation was issued late Friday to Quidel for the Sofia 2 SARS Antigen FIA, the agency said
PHOTO: FILE
WASHINGTON DC:
The US Food and Drug Administration (FDA) on Saturday approved emergency use authorisation (EUA) to Quidel Corp for the first Covid-19 antigen test.
The emergency use authorisation was issued late Friday to Quidel for the Sofia 2 SARS Antigen FIA, the agency said.
NIBD's passive immunisation technique gets US drug agency's nod for clinical trials
The FDA said the authorisation is for an antigen test, which is a new type of diagnostic test designed for rapid detection of the virus that causes Covid-19.
The FDA on Friday also authorised the first diagnostic test for the new coronavirus that allows patients to collect saliva samples at home.
The US Food and Drug Administration (FDA) on Saturday approved emergency use authorisation (EUA) to Quidel Corp for the first Covid-19 antigen test.
The emergency use authorisation was issued late Friday to Quidel for the Sofia 2 SARS Antigen FIA, the agency said.
NIBD's passive immunisation technique gets US drug agency's nod for clinical trials
The FDA said the authorisation is for an antigen test, which is a new type of diagnostic test designed for rapid detection of the virus that causes Covid-19.
The FDA on Friday also authorised the first diagnostic test for the new coronavirus that allows patients to collect saliva samples at home.